You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
復宏漢霖(02696.HK):HLX43用於治療晚期非小細胞肺癌(NSCLC)的國際多中心2期臨牀研究於中國境內完成首例患者給藥
格隆匯 06-10 17:02

格隆匯6月10日丨復宏漢霖(02696.HK)發佈公吿,近日,一項注射用HLX43(靶向PD-L1 抗體偶聯藥物)(“HLX43”)在晚期非小細胞肺癌(NSCLC)患者中開展的國際多中心2期臨牀研究於中國境內(不包括中國港澳台地區,下同)完成首例患者給藥。

本研究為一項評估HLX43在晚期非小細胞肺癌(NSCLC)患者的開放、國際多中心2期臨牀試驗,旨在評估HLX43在晚期非小細胞肺癌(NSCLC)患者中的有效性和安全性。研究分為兩個階段:第一階段將進行劑量探索,以選擇合適的HLX43劑量進行第二階段研究;第二階段為單臂、多中心2期臨牀研究。本研究的主要研究目的為評估HLX43在晚期非小細胞肺癌(NSCLC)中的臨牀療效;主要研究終點為由盲態獨立中心審查委員會根據RECIST v1.1標準評估的客觀緩解率。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account